12:00 AM
 | 
Dec 21, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Necitumumab: Phase III started

In November, Eli Lilly began the open-label Phase III INSPIRE trial to evaluate cisplatin and Alimta pemetrexed with or without 800 mg IV necitumumab...

Read the full 109 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >